Dj Tango Therapeutics Price Target Announced At $15.00/Share By Stifel

(17:09 GMT) Tango Therapeutics Price Target Announced at $15.00/Share by Stifel

Three clinical programs are advancing, with bopametastat showing strong efficacy in pancreatic cancer and a pivotal phase 3 trial set for 2026. Regulatory alignment is secured, and multiple data updates are planned, supported by a cash runway into 2028.

Based on Tango Therapeutics, Inc. [TNGX] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 3 2025

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 13 through Nov. 19, 2025. Source: VerityData

Activist Filings

Novavax(NVAX) Shah Capital Management raised its stake in the biotechnology company to 13,461,780 shares. Shah Capital Management did so through the purchase of 1,650,000 Novavax shares from Oct. 16 through Nov. 10 at per share prices ranging from $7.16 to $8.59. On Nov. 12, Shah issued an open letter to Novavax's board of directors, reiterating its frustrations with the company's weaker-than-expected Nuvaxovid Rollout, lack of proactive mind-set, high-cost structure, and misleading dilution data. Shah further emphasized its belief that "Novavax shareholders will be better served under the umbrella of a larger, competent pharma company."

Following the latest purchases, Shah Capital Management owns an 8.3% stake in Novavax's outstanding stock. Shares of Novavax have lost approximately 26% of their value since the beginning of this year.

Original Filings

UniFirst(UNF) River Road Asset Management filed an initial 13D regarding its stake in the workplace clothing provider, shifting to the stance of an activist investor from previous disclosures in a passive 13G. River Road reported that it purchased 98,131 UniFirst shares from Sept. 15 through Nov. 12 at per share prices ranging from $150.14 to $172.03, then sold 5,447 shares from Oct. 10 through Nov. 12 at $149.72 to $168.44.

Following those purchases, River Road owns 881,303 UniFirst shares, or 4.9% of those outstanding. Shares of UniFirst have lost approximately 6.2% of their value since the beginning of this year.

Increases in Holdings

Resideo Technologies(REZI) Clayton, Dubilier & Rice increased its stake in the home technology company to 33,478,322 shares. The private-equity firm purchased 1,689,758 Resideo shares from Nov. 10 through Nov. 13 at per share prices ranging from $30.27 to $32.51.

Following the latest purchases, CD&R owns 19.9% of Resideo Technologies' outstanding stock, bringing CD&R right up to the 19.9% "standstill" cap that the firm has agreed to. Shares of Resideo have gained roughly 27.8% in value since the beginning of this year.

Decreases in Holdings

Tango Therapeutics(TNGX) Third Rock Ventures IV lowered its stake in the biotechnology company to 9,374,574 shares. Third Rock Ventures did so through the sale of 5,352,942 Tango Therapeutics shares from Sept. 16 through Nov. 12 at per share prices ranging from $7.04 to $10.15.

Following the latest sales, Third Rock Ventures owns a 7% stake in Tango Therapeutics' outstanding stock. Shares of Tango Therapeutics have surged to gain approximately 164.7% in value since the beginning of this year.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.